Patient-targeted messaging for Emerging Multiple Sclerosis agents needs to highlight efficacy and preservation of quality of life

Surveyed neurologists perceive the efficacy of Merck Serono’s Rebif nearly as equivalent to that of Biogen Idec’s Tysabri, according to a new report from Decision Resources (more)

Vandervoort lauded for aging research

Faculty of Health Sciences professor Tony Vandervoort has won the prestigious Herbert A. de Vries Research Award for 2010 for distinguished research in the field of aging. (more)

Continued uptake of Tnf-Alpha Inhibitors and Interleukin Inhibitors will drive US $2.2 billion growth in the Psoriasis drug market

Abbott/Eisai’s Humira will achieve blockbuster sales and become the market leader in 2018, according to a new report from Decision Resources (more)

Dr. David Hill receives Frederick G. Banting Award

Dr. David Hill, Scientific Director of the lawson health research Institute has been honoured with the 2009 Federick G. Banting Award for his significant contributions to preventing diabetes in Canada. (more)

Genes not destiny when it comes to heart disease

When it comes to heart disease, lifestyle usually trumps genetics, says noted genetic researcher Dr. Robert Hegele, Heart and Stroke Foundation of Canada Lecturer at the Canadian Cardiovascular Congress 2009. (more)

Biosimilar TuNEX® from Mycenax completes Phase I/II clinical trial in Taiwan, Phase I in Korea

Protein drug development company Mycenax Biotech Inc. (GreTai, Taiwan: 4726) announced today that its rheumatoid arthritis and psoriasis drug TuNEX®, a biosimilar version of etanercept, has successfully completed a Phase I trial in South Korea and Phase I (more)

Tnf-Alpha Inhibitors will continue to dominate first- and second-line Biologic Therapy for the treatment of Rheumatoid Arthritis through 2011

However, Tnf-Alpha Inhibitors are not immune to competition from Roche’s emerging Il-6 Inhibitor Actemra, according to a new report from Decision Resources

Patient-Flow models will need to take into account that over ten percent of patients sta (more)

Majority of surveyed physicians prescribe Cymbalta and Lyrica for treatment of Fibromyalgia but neither agent has the majority of its uses in first line

Cymbalta is the agent most likely to lose patient share to Savella over the next two years, according to a new report from Decision Resources

Patient-flow models will need to take into account that the highest percentage of patients take Lyrica (more)

Continuing Global Attendance of Premier European Pharma Partnering Event

Fully booked euroPLX 41 Barcelona sees pharma and biotech business developers from 35 countries, many new-comers. (more)

Stiller to be inducted into Medical Halll of Fame

Dr. Calvin Stiller, one of Robarts founders and transplantation pioneer, has been named as one of the 2010 inductees for the Canadian Medical Hall of Fame. (more)